Abstract
Breast cancer is the second most common malignancy for women. Currently, only several prognostic and predictive factors are used clinically for managing breast cancer patients. Recently, systems biology approaches based on high-throughput technologies such as DNA microarrays, mass spectrometry-based proteomics and metabolomics have began to be used to investigate the expression of a wide range of genes and proteins in the dissected breast tumors. Moreover, these expression signatures have been found to provide potential and independent prognostic information in patients diagnosed with breast cancer. Furthermore, these molecular signatures could not only help to identify new therapeutic targets, but also allow physicians to design more effective and targeted therapeutic strategies for achieving better treatment outcomes of breast cancer patients.
| Original language | English |
|---|---|
| Title of host publication | Breast Cancer Metastasis and Drug Resistance |
| Subtitle of host publication | Progress and Prospects |
| Publisher | Springer New York |
| Pages | 329-340 |
| Number of pages | 12 |
| Volume | 9781461456476 |
| ISBN (Electronic) | 9781461456476 |
| ISBN (Print) | 1461456460, 9781461456469 |
| DOIs | |
| Publication status | Published - 2013 Aug 1 |
| Externally published | Yes |
Keywords
- DNA microarray
- Dissociable antibody microarray (DAMA)
- Estrogen receptor (ER)
- Factors for increased breast cancer incidence
- Gene annotation tool to help explain relationships (GATHER)
- Human epidermal growth factor receptor 2 (Her2)
- Mass spectrometry-based proteomics
- Metabolomics
- MicroRNA microarray
- Progesterone receptor (PR)
- Systems biology
- Systems biology approaches
- Tissue microarray
- Triple-negative breast cancers (TNBC)
- cDNA-mediated annealing selection extension and ligation (DASL)
ASJC Scopus subject areas
- Medicine(all)
